Cargando…

In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model

PURPOSE: Histone deacetylase inhibitors are promising new substances in cancer therapy and have also been shown to sensitize different tumor cells to irradiation (XRT). We explored the effect as well as the radiosensitizing properties of suberoylanilide hydroxamic acid (SAHA) in vivo in a malignant...

Descripción completa

Detalles Bibliográficos
Autores principales: Thiemann, Markus, Oertel, Susanne, Ehemann, Volker, Weichert, Wilko, Stenzinger, Albrecht, Bischof, Marc, Weber, Klaus-J, Perez, Ramon Lopez, Haberkorn, Uwe, Kulozik, Andreas E, Debus, Jürgen, Huber, Peter E, Battmann, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342162/
https://www.ncbi.nlm.nih.gov/pubmed/22458853
http://dx.doi.org/10.1186/1748-717X-7-52
_version_ 1782231644438003712
author Thiemann, Markus
Oertel, Susanne
Ehemann, Volker
Weichert, Wilko
Stenzinger, Albrecht
Bischof, Marc
Weber, Klaus-J
Perez, Ramon Lopez
Haberkorn, Uwe
Kulozik, Andreas E
Debus, Jürgen
Huber, Peter E
Battmann, Claudia
author_facet Thiemann, Markus
Oertel, Susanne
Ehemann, Volker
Weichert, Wilko
Stenzinger, Albrecht
Bischof, Marc
Weber, Klaus-J
Perez, Ramon Lopez
Haberkorn, Uwe
Kulozik, Andreas E
Debus, Jürgen
Huber, Peter E
Battmann, Claudia
author_sort Thiemann, Markus
collection PubMed
description PURPOSE: Histone deacetylase inhibitors are promising new substances in cancer therapy and have also been shown to sensitize different tumor cells to irradiation (XRT). We explored the effect as well as the radiosensitizing properties of suberoylanilide hydroxamic acid (SAHA) in vivo in a malignant rhabdoid tumor (MRT) mouse model. METHODS AND MATERIAL: Potential radiosensitization by SAHA was assessed in MRT xenografts by analysis of tumor growth delay, necrosis (HE), apoptosis (TUNEL), proliferation (ki-67) and γH2AX expression as well as dynamic (18)F-Fluorodeoxyglucose Positron Emission Tomography ((18)F-FDG -PET) after treatment with either SAHA alone, single-dose (10 Gy) or fractionated XRT (3 × 3Gy) solely as well as in combination with SAHA compared to controls. RESULTS: SAHA only had no significant effect on tumor growth. Combination of SAHA for 8 days with single-dose XRT resulted in a higher number of complete remissions, but failed to prove a significant growth delay compared to XRT only. In contrast fractionated XRT plus SAHA for 3 weeks did induce significant tumor growth delay in MRT-xenografts. The histological examination showed a significant effect of XRT in tumor necrosis, expression of Ki-67, γH2AX and apoptosis. SAHA only had no significant effect in the histological examination. Comparison of xenografts treated with XRT and XRT plus SAHA revealed a significantly increased γH2AX expression and apoptosis induction in the mice tumors after combination treatment with single-dose as well as fractionated XRT. The combination of SAHA with XRT showed a tendency to increased necrosis and decrease of proliferation compared to XRT only, which, however, was not significant. The (18)F-FDG-PET results showed no significant differences in the standard uptake value or glucose transport kinetics after either treatment. CONCLUSION: SAHA did not have a significant effect alone, but proved to enhance the effect of XRT in our MRT in vivo model.
format Online
Article
Text
id pubmed-3342162
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33421622012-05-03 In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model Thiemann, Markus Oertel, Susanne Ehemann, Volker Weichert, Wilko Stenzinger, Albrecht Bischof, Marc Weber, Klaus-J Perez, Ramon Lopez Haberkorn, Uwe Kulozik, Andreas E Debus, Jürgen Huber, Peter E Battmann, Claudia Radiat Oncol Research PURPOSE: Histone deacetylase inhibitors are promising new substances in cancer therapy and have also been shown to sensitize different tumor cells to irradiation (XRT). We explored the effect as well as the radiosensitizing properties of suberoylanilide hydroxamic acid (SAHA) in vivo in a malignant rhabdoid tumor (MRT) mouse model. METHODS AND MATERIAL: Potential radiosensitization by SAHA was assessed in MRT xenografts by analysis of tumor growth delay, necrosis (HE), apoptosis (TUNEL), proliferation (ki-67) and γH2AX expression as well as dynamic (18)F-Fluorodeoxyglucose Positron Emission Tomography ((18)F-FDG -PET) after treatment with either SAHA alone, single-dose (10 Gy) or fractionated XRT (3 × 3Gy) solely as well as in combination with SAHA compared to controls. RESULTS: SAHA only had no significant effect on tumor growth. Combination of SAHA for 8 days with single-dose XRT resulted in a higher number of complete remissions, but failed to prove a significant growth delay compared to XRT only. In contrast fractionated XRT plus SAHA for 3 weeks did induce significant tumor growth delay in MRT-xenografts. The histological examination showed a significant effect of XRT in tumor necrosis, expression of Ki-67, γH2AX and apoptosis. SAHA only had no significant effect in the histological examination. Comparison of xenografts treated with XRT and XRT plus SAHA revealed a significantly increased γH2AX expression and apoptosis induction in the mice tumors after combination treatment with single-dose as well as fractionated XRT. The combination of SAHA with XRT showed a tendency to increased necrosis and decrease of proliferation compared to XRT only, which, however, was not significant. The (18)F-FDG-PET results showed no significant differences in the standard uptake value or glucose transport kinetics after either treatment. CONCLUSION: SAHA did not have a significant effect alone, but proved to enhance the effect of XRT in our MRT in vivo model. BioMed Central 2012-03-29 /pmc/articles/PMC3342162/ /pubmed/22458853 http://dx.doi.org/10.1186/1748-717X-7-52 Text en Copyright ©2012 Thiemann et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Thiemann, Markus
Oertel, Susanne
Ehemann, Volker
Weichert, Wilko
Stenzinger, Albrecht
Bischof, Marc
Weber, Klaus-J
Perez, Ramon Lopez
Haberkorn, Uwe
Kulozik, Andreas E
Debus, Jürgen
Huber, Peter E
Battmann, Claudia
In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model
title In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model
title_full In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model
title_fullStr In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model
title_full_unstemmed In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model
title_short In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model
title_sort in vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342162/
https://www.ncbi.nlm.nih.gov/pubmed/22458853
http://dx.doi.org/10.1186/1748-717X-7-52
work_keys_str_mv AT thiemannmarkus invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel
AT oertelsusanne invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel
AT ehemannvolker invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel
AT weichertwilko invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel
AT stenzingeralbrecht invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel
AT bischofmarc invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel
AT weberklausj invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel
AT perezramonlopez invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel
AT haberkornuwe invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel
AT kulozikandrease invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel
AT debusjurgen invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel
AT huberpetere invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel
AT battmannclaudia invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel